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Summary
Signalling through the interleukin (IL)-6 pathway induces proliferation and drug resistance of
multiple myeloma cells. We therefore sought to determine whether the IL-6-neutralizing
monoclonal antibody siltuximab, formerly CNTO 328, could enhance the activity of melphalan,
and to examine some of the mechanisms underlying this interaction. Siltuximab increased the
cytotoxicity of melphalan in KAS-6/1, INA-6, ANBL-6, and RPMI 8226 human myeloma cell
lines (HMCLs) in an additive-to-synergistic manner, and sensitized resistant RPMI 8226.LR5 cells
to melphalan. These anti-proliferative effects were accompanied by enhanced activation of drug-
specific apoptosis in HMCLs grown in suspension, and in HMCLs co-cultured with a human-
derived stromal cell line. Siltuximab with melphalan enhanced activation of caspase-8, caspase-9,
and the downstream effector caspase-3 compared with either of the single agents. This increased
induction of cell death occurred in association with enhanced Bak activation. Neutralization of
IL-6 also suppressed signalling through the phosphoinositide 3-kinase/Akt pathway, as evidenced
by decreased phosphorylation of Akt, p70 S6 kinase and 4E-BP1. Importantly, the siltuximab/
melphalan regimen demonstrated enhanced anti-proliferative effects against primary plasma cells
derived from patients with myeloma, monoclonal gammopathy of undetermined significance, and
amyloidosis. These studies provide a rationale for translation of siltuximab into the clinic in
combination with melphalan-based therapies.
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Therapeutic outcomes in patients with multiple myeloma have been steadily improving, due
mainly to the advent of novel agents, including proteasome inhibitors, such as bortezomib
(Shah & Orlowski, 2009), and immunomodulatory drugs, such as thalidomide and
lenalidomide (Dimopoulos et al, 2008). Initially approved in the relapsed and/or refractory
setting (Laubach et al, 2009), these drugs have now been incorporated into induction and
maintenance therapy (Palumbo & Rajkumar, 2009), and have contributed to a doubling of
overall survival in this disease. However, even the best combination strategies achieve
complete remissions in less than half of patients, indicating an important role for primary
drug resistance in promoting myeloma cell survival. Cytokines produced in the bone marrow
microenvironment are likely to play an important role in mediating primary drug resistance.
Myeloma is characterized by the accumulation of clonal plasma cells in the bone marrow,
where they are protected by a microenvironment that promotes plasma cell survival and
proliferation (Hideshima et al, 2007). Adhesion of myeloma cells to bone marrow stromal
cells (BMSCs) induces the latter to secrete pro-survival cytokines, including interleukin
(IL)-6 (Hideshima et al, 2007). IL-6 activates multiple cell survival and proliferation
signalling pathways in myeloma cells, including the Janus kinase/signal transducer and
activator of transcription 3 (JAK/STAT-3) pathway, the mitogen-activated protein kinase
kinase/extracellular signal-related kinase (MEK/ERK) pathway, and the phosphoinositide 3-
kinase (PI3-K)/Akt pathway (Hideshima et al, 2007). Not only is IL-6 important for the
pathogenesis of multiple myeloma, with increased IL-6 expression found in the bone
marrow mononuclear cells of myeloma patients (Portier et al, 1991), but increased serum
levels of IL-6 and soluble IL-6 receptor, an IL-6 agonist frequently found complexed to IL-6
in serum, are also indicators of poor prognosis for myeloma patients (Greipp et al, 1998;
Stasi et al, 1998; Wierzbowska et al, 1999), suggesting that IL-6 may be a good therapeutic
target for this disease.
Siltuximab, formerly CNTO 328, a chimeric human-mouse monoclonal IL-6 neutralizing
antibody, has demonstrated promising anti-myeloma activity in combination with
bortezomib (Voorhees et al, 2007) and dexamethasone (Voorhees et al, 2009) in preclinical
myeloma models. As a result of the excellent rationale for IL-6 blockade in myeloma
(Trikha et al, 2003), as well as these pre-clinical data, siltuximab is now being studied in
clinical trials focusing initially on combinations with bortezomib (Rossi et al, 2008) and
dexamethasone (Voorhees et al, 2009). Pre-clinically, siltuximab inhibited phosphorylation
of ERK-1/2, STAT-1, and STAT-3 in human multiple myeloma cell lines (HMCLs) in the
presence of IL-6, thus blocking critical signals for cell growth and survival (Voorhees et al,
2007). In addition, siltuximab inhibited the bortezomib-induced up-regulation of myeloid
cell leukaemia-1 (Mcl-1) and heat shock protein 70 (HSP-70), both of which may be
involved in inducible chemoresistance (Voorhees et al, 2007). Due to this promising pre-
clinical activity shown by siltuximab, as well as other anti-IL-6 approaches, such as the
single-chain fragment NRI (Yoshio-Hoshino et al, 2007) and the humanized antibody 1339
(Fulciniti et al, 2009), we sought to evaluate the effect of combining siltuximab with
melphalan in HMCLs.
The bifunctional alkylating agent melphalan is widely used for the treatment of myeloma,
with the formation of DNA interstrand crosslinks regarded as the critical toxic lesion
(Spanswick et al, 2002; Sunters et al, 1992). Melphalan is administered both as high dose
therapy (HDM) prior to autologous stem cell transplant (ASCT), and as low dose therapy in
combination with prednisone and, more recently, prednisone plus thalidomide, lenalidomide,
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or bortezomib, in patients who are not candidates for ASCT (Hulin et al, 2009; Merchionne
et al, 2007; Palumbo et al, 2009). While initial responses are good, virtually all patients
relapse, often with refractory disease (Merchionne et al, 2007). HDM followed by ASCT
causes an increase in IL-6 production during haematological recovery that may promote the
survival of melphalan-resistant cells, suggesting that inhibition of IL-6 in combination with
standard or high dose melphalan may improve clinical outcomes (Rossi et al, 2005).
Chemotherapy induces apoptosis through activation of the extrinsic (caspase-8) death
receptor pathway, and/or the intrinsic (caspase-9) mitochondrial pathway, both of which
lead to downstream activation of caspase-3. Unless the extrinsic pathway produces robust
activation of caspase-8, both pathways require mitochondrial outer membrane
permeabilization (MOMP) to commit the cell to apoptosis (Scaffidi et al, 1998; Sheridan &
Martin, 2008). Bak and Bax, two pro-apoptotic members of the Bcl-2 family of proteins, are
activated by a conformational change that exposes an N-terminal epitope and promotes self-
oligomerization in the mitochondrial outer membrane and induction of MOMP (Green &
Kroemer, 2004; Leber et al, 2007). Studies using Bak/Bax double knockout mice and mouse
embryo fibroblasts have demonstrated that activation of at least one of these proteins is
necessary for induction of apoptosis (Cheng et al, 2001; Lindsten et al, 2000; Willis et al,
2005). Anti-apoptotic Bcl-2 family proteins, such as Mcl-1, Bcl-xL and Bcl-2, promote cell
survival by inhibiting oligomerization of Bak and Bax, while the pro-apoptotic BH3-only
proteins, including Bim, Bid, PUMA, Noxa and Bad, promote apoptosis by binding to and
neutralizing the anti-apoptotic proteins, releasing Bak and Bax inhibition (Chipuk & Green,
2008; Willis et al, 2005, 2007). While we have previously demonstrated that siltuximab
decreased expression of anti-apoptotic Mcl-1 (Voorhees et al, 2007), a protein critical for the
survival of myeloma cells (Derenne et al, 2002; Zhang et al, 2002), the effect of siltuximab
and the siltuximab/melphalan combination on downstream Bak and Bax activation in
HMCLs is unknown.
Here we demonstrate that the combination of siltuximab and melphalan attenuated cell
proliferation in an additive to synergistic manner, and enhanced apoptosis in HMCLs. This
increased cell death correlated with enhanced Bak activation, and siltuximab also inhibited
IL-6 activation of the pro-survival PI3-K/Akt signalling pathway. Importantly, the
siltuximab/melphalan combination was also effective in patient-derived myeloma samples,
and partially overcame melphalan resistance. These results support translation of siltuximab
into the clinic in combination with melphalan-based therapies.
Materials and methods
Materials
Siltuximab and the F105 isotype control antibody recognizing the human immunodeficiency
virus type 1 gp120 envelope protein were provided by Centocor Ortho Biotech, Inc.
(Horsham, PA, USA), and diluted in 0·15 mol/l sodium chloride and 0·01 mol/l sodium
phosphate (pH 7·2). Melphalan, from Sigma-Aldrich (St. Louis, MO, USA), was dissolved
at a concentration of 25 mmol/l in acid ethanol (99·5% ethanol, 0·5% 12·1 N HCl v/v),
diluted to a 5 mmol/l stock in acid saline (0·15 mol/l NaCl, 0·01 N HCl), and further
dilutions were in 20% acid ethanol/80% acid saline.
Cell lines and patient myeloma samples
The IL-6 dependent HMCLs KAS-6/1, INA-6, and ANBL-6 were provided by Dr. Diane
Jelinek (Mayo Clinic, Rochester, MN, USA), Dr. Martin Gramatzki (University of
Erlangen-Nurnberg, Germany), and Dr. Beverly S. Mitchell (Stanford University, Palo Alto,
CA, USA), respectively. HS5-GFP human stromal cells, and RPMI 8226.LR5 melphalan-
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resistant myeloma cells (Bellamy et al, 1991), were provided by Dr. William Dalton (H. Lee
Moffitt Cancer Center, Tampa, FL, USA), while RPMI 8226 cells were from the American
Type Culture Collection (Manassas, VA, USA). These cell lines were validated through The
M. D. Anderson Cancer Center Characterized Cell Line Core Facility. KAS-6/1, INA-6,
ANBL-6, and RPMI 8226 cells, and human stromal cells expressing green fluorescent
protein (HS5-GFP), were propagated in culture as described previously (Voorhees et al,
2007, 2009). RPMI 8226.LR5 cells were grown in the presence of 5 μmol/l melphalan,
which was removed for at least 1 week prior to the indicated experiments. Media was
supplemented with 1 ng/ml human recombinant IL-6 from R&D Systems (Minneapolis,
MN) for IL-6-dependent cells, except when HMCLs were grown in the presence of stromal
cells. Primary plasma cells were purified from patient bone marrow aspirates collected under
a protocol approved by the Institutional Review Board of The University of Texas M. D.
Anderson Cancer Center after informed consent was obtained in compliance with the
Declaration of Helsinki. Mononuclear cells were isolated using density gradient
centrifugation with Ficoll-Paque™ Plus from GE Healthcare Life Sciences (Piscataway, NJ,
USA), followed by immunomagnetic separation using a RoboSep® machine and EasySep®
anti-CD138 magnetic beads from STEMCELL Technologies, Inc. (Vancouver, BC, USA).
Cell viability assays
Cell viability was measured using the WST-1 reagent from Roche Applied Science
(Indianapolis, IN, USA) as previously described (Kuhn et al, 2007, 2009). Data were
calculated as a percent viability relative to the vehicle- or control antibody-treated cells,
while mean inhibitory concentrations (IC50 values) were calculated with GraphPad Prism
from GraphPad Software (La Jolla, CA, USA) using non-linear regression.
Apoptosis assays
INA-6 and KAS-6/1 cells grown in suspension were treated as described in the text, and
when co-cultures were established, myeloma cells were plated onto HS5-GFP stromal cells
that had been allowed to attach overnight before treatment. Programmed cell death was
evaluated by staining with fluorescein isothiocyanate (FITC)-conjugated Annexin-V from
BioVision, Inc. (Mountain View, CA, USA), followed by flow cytometry according to the
manufacturer's protocol. In experiments where HS5-GFP cells were included, phycoerythrin
(PE)-conjugated Annexin V was used instead. The DNA-binding dye TO-PRO-3 was used
to distinguish cells with intact membranes from those with compromised membranes. Data
were collected from 10 000 events on a FACSCaliber machine using CellQuest software
from Becton Dickinson (Franklin Lakes, NJ, USA), and analysed using FlowJo software
from Tree Star, Inc. (Ashland, OR, USA).
Caspase activity assays were performed using CASPGLOW Active Caspase Staining Kits
(BioVision, Inc.). Cells were incubated with irreversible fluorescent caspase inhibitors that
specifically bind active caspases, and analysed by flow cytometry following the
manufacturer's protocol.
Western blotting
Cells were lysed in radioimmunoprecipitation assay buffer (1× phosphate-buffered saline,
1% Igepal, 0·1% sodium dodecyl sulphate, and 0·5% deoxycholate) supplemented with
SIGMAFAST™ Protease Inhibitor Tablets and Phosphatase Inhibitor Cocktails I and II
(Sigma-Aldrich). Proteins were separated by electrophoresis through NuPAGE® precast gels
from Invitrogen (Carlsbad, CA, USA), and bands were visualized using either ECL™ (GE
Healthcare Life Sciences) or Supersignal West Dura Extended Duration Substrate from
Thermo Scientific (Rockford, IL, USA). Antibodies used included anti-Akt and –phospho-
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Akt, -Bid, -p70 S6 kinase and –phospho-p70 S6K, -4E-BP1 and -phospho-4E-BP1, from
Cell Signalling Technology, Inc. (Danvers, MA, USA), and anti-β-actin (Sigma-Aldrich).
Bak and Bax activation assays
Bak and Bax activation were evaluated by flow cytometry. Treated cells were fixed in 2%
paraformaldehyde and resuspended in permeabilization buffer (1× phosphate-buffered
saline, 0·5% bovine serum albumin, and 0·3% saponin) containing 2 μg/ml anti-Bak Ab-1
antibody from CalBiochem/EMD4 Biosciences (Madison, WI, USA), 20 μg/ml anti-Bax
6A7 antibody (Sigma-Aldrich), or a control mouse IgG. Cells were then incubated with anti-
mouse Alexa Fluor® 488 conjugated secondary antibody (Invitrogen) prior to flow
cytometry. Bak activation was calculated relative to the IgG control, while Bax activation
was calculated relative to Bax staining of the untreated control cells.
Immunoprecipitation was also performed to evaluate Bak and Bax activation using a
modification of the method described by Pei et al (Pei et al, 2007). Briefly, frozen cell
pellets were lysed in CHAPS buffer (10 mmol/l HEPES, pH 7·4, 150 mmol/l NaCl, 1%
CHAPS and 1× SIGMAFAST™ Protease Inhibitor Tablets), DNA was sheered, and
samples were clarified to remove insoluble material. Extracts were pre-cleared with protein
A/G agarose, and then incubated with anti-Bak (1 μg) or anti-Bax (2 μg) antibody
overnight. Protein A/G agarose was added for an additional four hours and, after washing,
the agarose-bound proteins were dissociated by boiling in sample buffer under denaturing
and reducing conditions. The contents of the precipitates were then separated and analysed
by Western blotting as described above.
Statistical analyses
Calcusyn software from Biosoft (Ferguson, MO, USA) was used to calculate combination
indices (CIs) for the siltuximab/melphalan combinations using isobologram analysis, with
CIs of ≤0·9 considered moderately synergistic, <0·7 considered synergistic, and <0·1
considered very strongly synergistic.
Results
Siltuximab enhances melphalan cytotoxicity
The impact of blocking IL-6 signalling on HMCLs was evaluated in IL-6-dependent
KAS-6/1, INA-6 and ANBL-6 cells, which were exposed to clinically relevant
concentrations of siltuximab, a neutralizing monoclonal antibody specific for human IL-6.
INA-6 cells were the most sensitive to a 72-h exposure to siltuximab, with KAS-6/1 cells
showing an intermediate sensitivity, and ANBL-6 cells demonstrating the highest IC50 (Fig
1A and Table SI). Also, INA-6 cells exhibited a more rapid response to siltuximab than
KAS-6/1 or ANBL-6 cells, in that the majority of the reduction in viability seen by 72 h was
also visible after only 2 d (Table SI). Treatment of these cell lines with single-agent
melphalan showed a narrower range of IC50 values, varying from 2·9 to 9·4 μmol/l at 48 h
(Table SI). In all three of the cell lines, a 24-h pretreatment with siltuximab, followed by a
48-h treatment with melphalan, enhanced toxicity over either drug alone (Fig 1B–D). For
example, in KAS-6/1 cells, siltuximab alone induced a 30% decrease in viability, melphalan
at 4 μmol/l led to a 52% decrease in viability, while the combination resulted in an 83%
decrease (Fig 1B). Similarly, siltuximab led to a 30% decrease in viability of INA-6 cells,
melphalan at 1 μmol/l induced a 30% decrease, while the combination produced a 69%
decrease in viability (Fig 1C).
Isobologram analysis was performed to evaluate the possibility that the siltuximab/
melphalan combination was synergistic. KAS-6/1 cells were treated with escalating anti-
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body doses and melphalan at a fixed 1:1 ratio based on the IC50 values of siltuximab at 72 h
and melphalan at 48 h. Cells were pretreated for 24 h with siltuximab concentrations ranging
from 0·5 to 2·0× the IC50, followed by addition of melphalan at the same ratios. The
combination was synergistic at all doses tested, with CIs ranging from 0·253 to 0·487 (Table
I). Because the order of drug administration can affect the outcome of combination
chemotherapy, we investigated the effect of the sequence of addition using the siltuximab/
melphalan regimen. KAS-6/1 cells were either pretreated with antibody for 24 h followed by
incubation with melphalan for 48 h, simultaneously treated with both siltuximab and
melphalan for 48 h, or pretreated with melphalan for 8 h followed by incubation with
siltuximab for 40 h. While the siltuximab/melphalan combination was synergistic in all
cases (Table SII), the synergy was strongest with siltuximab pretreatment, and weakest with
melphalan pretreatment. Although experiments with fixed siltuximab:melphalan ratios were
not performed in INA-6 and ANBL-6 cells, analysis of a smaller range of concentrations
demonstrated that the combination was synergistic in INA-6 cells, and at least additive when
melphalan concentrations ≥7·5 μmol/l were used in ANBL-6 cells (Table SIII).
The siltuximab/melphalan combination was next evaluated in IL-6 independent RPMI 8226
cells, and in their melphalan-resistant counterparts, RPMI 8226.LR5. As expected, RPMI
8226 cells were less sensitive to siltuximab than the IL-6 dependent HMCLs, but still
suffered a 20–25% decrease in cell viability at siltuximab concentrations up to 15 μg/ml
(Fig - S1A). When the combination of siltuximab and melphalan was evaluated, siltuximab
enhanced the toxicity of melphalan in RPMI 8226 cells (Fig S1B,C). Isobologram analysis,
performed over a range of drug concentrations, demonstrated synergistic interactions, with
CIs ranging from 0·719 down to 0·368 (Table SVI). Siltuximab alone had a minimal effect
on RPMI 8226.LR5 cells (Fig S1A), but when the combination was studied, IL-6 blockade
potentiated the cytotoxic effects of melphalan (Fig S1B,C). Combination indices ranged
from 0·911 to 0·675 (Table SVI), indicating the presence of moderate synergy, and
supporting the possibility that siltuximab could partially overcome melphalan resistance.
Role of apoptosis in the enhanced cytotoxicity of the siltuximab/melphalan combination
To evaluate the contribution of apoptosis to the cytotoxic effect of the siltuximab/melphalan
combination, cell surface Annexin V staining was analysed by flow cytometry. Siltuximab
alone induced some apoptosis in KAS-6/1 and INA-6 cells (Fig 2A,B), and when siltuximab
was combined with melphalan, apoptosis was significantly enhanced over either drug alone.
In KAS-6/1 cells, siltuximab and melphalan as single agents resulted in 34·8% and 51·6%
apoptosis respectively, while the combination resulted in 74·5% apoptotic cells (Fig 2A,
lower panel). Similarly, in INA-6 cells, siltuximab and melphalan alone resulted in 26·8%
and 42·6% apoptotic cells respectively, while the combination induced apoptosis in 67·1%
of cells (Fig 2B, lower panel).
Induction of apoptosis with the siltuximab/melphalan combination was then evaluated by
measuring the activation status of caspase-3, the common effector of programmed cell
death. Both siltuximab and melphalan activated caspase-3 as single agents, and this was
significantly enhanced in KAS-6/1 and INA-6 cells when the drugs were combined (Fig
3A,B, upper panels). As caspase-3 can be activated either through the intrinsic, caspase-9-
mediated arm of apoptosis, or through the extrinsic, caspase-8-mediated apoptotic pathway,
the activation status of these caspases was determined as well. Notably, while siltuximab
and melphalan activated caspase-8 (Fig 3A,B, middle panels) and caspase-9 (Fig 3A,B,
lower panels) as single agents, the combination regimen demonstrated enhanced activation
of both the intrinsic and extrinsic apoptotic pathways.
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Siltuximab/melphalan overcomes the protective effect of stromal cells
In order to more closely mimic the bone marrow microenvironment, HMCLs were cultured
in the presence of the stromal cell line HS5-GFP. Stromal cells, with their ability to
elaborate a number of cytokines that promote plasma cell proliferation and survival, had a
protective effect on KAS-6/1 cells treated with single-agent siltuximab (Fig 4A, upper
panel). With HS5-GFP cells present, only 11% of KAS-6/1 cells treated with siltuximab at
10 μg/ml stained positive for Annexin V, compared to 42% of KAS-6/1 cells grown in the
absence of stromal cells. A slight trend for a protective effect was also seen in the INA-6
model (Fig 4B, upper panel), though this did not reach statistical significance. When both
cell lines were exposed to siltuximab/melphalan, however, blockade of IL-6 signalling was
successful at enhancing apoptosis at the majority of melphalan concentrations tested (Fig
4A,B, lower panels).
Bak and Bax activation are associated with the response to siltuximab/melphalan
Type I programmed cell death is often associated with activation of pro-apoptotic Bcl-2
family members such as Bak and Bax, and this possibility was evaluated in KAS-6/1 cells
by flow cytometry with active conformation-specific antibodies. Siltuximab alone induced
substantial dose-dependent Bak activation (Fig 5A, left panel), and also statistically
significant increases in Bax activation (Fig 5A, right panel), though the latter occurred in a
minority of the cell population. When KAS-6/1 cells were pretreated with siltuximab
followed by melphalan, Bak activation was significantly potentiated over that achieved with
either drug alone (Fig 5B, left panel). While melphalan treatment alone showed a small,
dose-dependent activation of Bax in KAS-6/1 cells, the siltuximab/melphalan regimen did
not significantly increase this activation further (Fig 5B, right panel). In order to confirm
these findings, immunoprecipitation experiments were performed in both KAS-6/1 (Fig 5C)
and INA-6 cells (Fig 5D). Both melphalan and siltuximab activated Bak to some extent as
single agents, but the level of active Bak was increased when the drugs were combined,
supporting a role for this mechanism in the enhanced induction of apoptosis. In contrast,
activated Bax was not consistently detected in either the KAS-6/1 or INA-6 cells following
treatment with siltuximab and melphalan (data not shown).
Siltuximab-induced apoptosis is associated with the cleavage of Bid to its active form
Because both siltuximab and melphalan activated caspase-8, we tested whether the
caspase-8 substrate Bid was cleaved to pro-apoptotic tBid following siltuximab and
melphalan treatment. Cleavage of Bid to tBid was observed in INA-6 cells treated for 72 h
with siltuximab, but was not observed following melphalan treatment alone, and was not
enhanced when the two drugs were combined (Fig 6A). To determine whether Bid cleavage
was an early event in apoptosis, INA-6 cells treated with siltuximab were harvested from 8
to 32 h, followed by Western blotting for Bid expression. tBid was present as early as 8 h
following siltuximab treatment, and levels continued to increase through to 32 h as full-
length Bid levels decreased (Fig 6B). Siltuximab treatment also led to a decrease in Bid
levels in KAS-6/1 cells (Fig S2A), suggesting cleavage of Bid to pro-apoptotic tBid.
However, due to the difficulty of detecting tBid and the relatively low level of Bid in
KAS-6/1 cells (Fig S2B), tBid was not detected.
Suppression of Akt signalling by siltuximab
Activity of the PI3K/Akt pathway has been implicated in plasma cell resistance to
melphalan (Hamasaki et al, 2005; Hideshima et al, 2006), and it was therefore of interest to
determine if siltuximab might be enhancing the effects of melphalan in part through this
mechanism. Consistent with this possibility, single-agent siltuximab inhibited the activity of
the Akt pathway, as judged by a decrease in the levels of phosphorylated, activated Akt in
Hunsucker et al. Page 7













KAS-6/1 cells (Fig 6C). Also, in both KAS-6/1 (Fig 6C) and INA-6 cells (Fig 6D), the
levels of two phosphorylated downstream targets of Akt, phospho-p70 S6 kinase and
phospho-4E-BP1, were decreased by IL-6 blockade. Notably, siltuximab combined with 2
μmol/l melphalan reduced the levels of p70 S6 kinase and 4E-BP1 to an even greater extent
than was the case for either siltuximab alone or melphalan alone. Qualitatively similar
results were obtained in ANBL-6 cells using siltuximab alone, although with less of an
effect of the combination with melphalan (Fig S1C).
Siltuximab and melphalan are active against primary plasma cells
Blockade of IL-6 signalling in the clinical setting, either with the anti-receptor antibody
tocilizumab (Nishimoto et al, 2005), or with the neutralizing antibody siltuximab and the
proteasome inhibitor bortezomib (Rossi et al, 2008), have been shown to induce mild
cytopenias. To examine the effects of siltuximab and melphalan on non-transformed cells,
this combination was tested against peripheral blood mononuclear cells (PBMCs) isolated
from two healthy donors. Siltuximab alone reduced cell viability by 12–20% (Fig S3A,B),
and when melphalan was added, there was a further decrease compared to that induced with
either drug alone. We then examined the activity of the siltuximab/melphalan combination
against malignant primary cells by challenging CD138+ plasma cells isolated from the bone
marrow aspirates of three patients with multiple myeloma (Fig 7A), one patient with
amyloidosis (Fig 7B), and one patient with monoclonal gammopathy of undetermined
significance (MGUS; Fig 7C). In cells isolated from the three myeloma patients, reductions
in cell viability following single-agent siltuximab treatment ranged from 28 to 43% (Fig
7A), which were comparable to those we have previously reported after IL-6 blockade in
primary samples (Voorhees et al, 2007; Voorhees et al, 2009). Plasma cells from patient
MM-62 with newly diagnosed disease (Fig 7A, left panel) suffered a statistically significant
reduction in viability with siltuximab and melphalan at all concentrations of the alkylating
agent that were tested. Patients MM-50 (Fig 7A, middle panel) and MM-52 (Fig 7A, right
panel) both had received multiple prior lines of therapy, including melphalan-based
regimens from which their diseases had relapsed. Their plasma cells were less sensitive to
the siltuximab/melphalan combination, but with melphalan at 2·5 μmol/l, both showed
enhanced activity of the regimen compared to melphalan alone. We also had the opportunity
to study CD138+ plasma cells isolated from a patient with newly diagnosed systemic
amyloidosis (Fig 7B). Siltuximab alone reduced cell viability by 24% in 72 h, and when
melphalan was added for 48 h, cell viability was significantly reduced compared to either
drug alone. Similarly, plasma cells isolated from a patient with MGUS were more sensitive
to the combination. Purified CD138+ cells showed a 40% reduction in viability with
siltuximab and 5 μmol/l melphalan, compared with only 8% for siltuximab alone and 11%
for melphalan alone (Fig 7C). Notably, these reductions in the viability of transformed cells
were more robust than was the case for the PBMC samples, supporting the possibility of a
therapeutic index. When the two latter samples were compared to the three primary isolates
(MM-62, MM-50 and Amyloidosis-59) for which there was data combining siltuximab with
7·5 μmol/l melphalan, the plasma cell dyscrasia-derived cells showed a mean residual
viability of 34%, compared to 65% for the PBMCs (Fig S3C), though due to the small
sample size, this trend did not reach statistical significance (P = 0·1125). To further evaluate
the selectivity of this therapeutic regimen, HS5-GFP stromal cells were pretreated with
siltuximab for 24 h, followed by 48 h of treatment with melphalan. Blockade of IL-6
signalling alone did not impact on stromal cell viability (Fig 7D), while melphalan alone did
induce a dose-dependent reduction in viability (Fig 7D). When siltuximab was added to
melphalan, no enhanced reduction of viability was seen at lower melphalan concentrations,
though a modest enhancement was seen at the highest melphalan concentration tested.
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In the bone marrow microenvironment, IL-6 activates multiple cell signalling pathways that
promote myeloma cell proliferation, survival and resistance to chemotherapy. Inhibition of
IL-6 with the clinical grade antibody siltuximab enhanced melphalan toxicity in IL-6-
dependent and -independent HMCLs, in melphalan-resistant RPMI 8226.LR5 cells, and in
CD138+ plasma cells isolated from several patients diagnosed with plasma cell dyscrasias.
Siltuximab also inhibited signalling through the PI3-K/Akt pathway as evidenced by
reduced Akt, p70 S6 kinase and 4E-BP1 phosphorylation following antibody treatment. This
pathway may be important for drug resistance, because activation of the PI3-K/Akt pathway
in myeloma cells by IL-6 has been reported to confer resistance to dexamethasone-mediated
apoptosis (Hideshima et al, 2001). Multiple mechanisms have been reported for inhibition of
apoptosis by Akt, including phosphorylation and inactivation of the pro-apoptotic protein
Bad (Datta et al, 1997); phosphorylation and inactivation of the FoxO forkhead transcription
factor responsible for upregulation of pro-apoptotic Bim in response to growth factor
withdrawal (Downward, 2004); and inhibition of Bak and Bax activation following Bid
cleavage via a mechanism that promotes association of hexokinases with the mitochondrial
membrane (Majewski et al, 2004). The PI3-K/mTOR inhibitor NVP-BEZ235 (Baumann et
al, 2009) and the Akt inhibitor perifosine (Hideshima et al, 2006) both enhance the
cytotoxicity of melphalan in HMCLs, suggesting that the PI3-K/Akt pathway is also
involved in melphalan resistance. As such, downregulation of Akt activation could be an
important mechanism of enhanced cytotoxicity when siltuximab and melphalan are
combined, though other mechanisms of melphalan resistance, such as through the Fanconi
anaemia/BRCA pathway, would not be impacted (Chen et al, 2005). Akt phosphorylation
was not detected in INA-6 cells grown in the presence of IL-6, either because IL-6 does not
induce Akt phosphorylation in INA-6 cells, or phosphorylated Akt levels were too low to be
detected by Western blot. To rule out the possibility that Akt phosphorylation was transient
in INA-6 cells and therefore could not be detected 8 h after addition of media with fresh
IL-6, cells were IL-6 starved for 4–16 h followed by addition of IL-6. Under these
conditions, Akt phosphorylation was induced within 30 min in KAS-6/1 and ANBL-6 cells,
but not in INA-6 cells (data not shown). Akt activation leads to activation of the downstream
mTOR/Raptor complex, which in turn phosphorylates p70 S6 kinase and 4E-BP1, leading to
activation of cap-dependent translation (Kroczynska et al, 2009). The inhibition of p70 S6
kinase and 4E-BP1 phosphorylation by siltuximab in INA-6 cells demonstrates that an IL-6-
dependent pathway is mediating mTOR/Raptor activity in these cells, and suggests the
possibility that the Akt phosphorylation was below detectable levels.
Although the activity of siltuximab in combination with bortezomib in HMCLs correlated
with its ability to downregulate Mcl-1L expression (Voorhees et al, 2007), that did not
appear to be the case with the siltuximab/melphalan combination. While siltuximab
downregulated Mcl-1L in both INA-6 and ANBL-6 cells, it had little effect on Mcl-1L
expression in KAS-6/1 cells (data not shown). Notably, however, siltuximab and melphalan
were able to interact in a synergistic fashion in HMCL models that expressed mutant, non-
functional forms of p53 (ANBL-6 and INA-6 cells; (Stuhmer et al, 2005)), temperature-
sensitive forms of p53 (RPMI 8226 cells; (Teoh et al, 2000)), or in which wild-type p53
expression has been found to be suppressed (KAS-6/1; (Hodge et al, 2005)). Enhanced
apoptosis with the siltuximab/melphalan combination seemed to depend on the ability of
siltuximab to activate the mitochondrial-dependent apoptotic pathway at least in part
through activation of caspase-8 followed by cleavage of Bid to tBid and activation of Bak.
Melphalan-induced caspase-8 activation, however, did not lead to Bid cleavage, indicating
that Bak activation in response to melphalan was mediated by a different Bcl-2 family
protein(s). The relatively weak activation of Bax in comparison to Bak by both siltuximab
and melphalan may reflect a low level of Bax expression in these cells and is likely to be
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cell line specific, as Bax activation in response to melphalan has been previously reported in
an HMCL (Gomez-Bougie et al, 2005).
While the sample size was small, the three patients (one myeloma, one amyloidosis, and one
MGUS) who had no prior therapy, showed a statistically significant effect of the
combination over either drug alone (P < 0·05), whereas in the two myeloma patients who
had received prior melphalan therapy (MM-50 and MM-52), siltuximab plus melphalan was
significantly more effective than melphalan alone at some doses, but was not significantly
more effective than siltuximab alone. In the clinical setting, siltuximab would probably be
added to melphalan-based therapies that include other drugs, such as melphalan/
dexamethasone or bortezomib/melphalan/prednisone, and it would be interesting to
determine the effectiveness of siltuximab on patient-derived CD138+ cells with these drug
combinations.
Siltuximab specifically neutralizes only human IL-6, precluding studies of this targeted
agent in standard systemic murine in vivo model systems. Moreover, study of this agent in
models incorporating human fetal tissue is barred, obviating the use of techniques that
provide a human microenvironment by implanting a fetal bone chip into the flanks of
immunodeficient mice (Tassone et al, 2005). However, IL-6 levels rise dramatically in the
peri-transplant setting in myeloma patients receiving high dose melphalan therapy
(Condomines et al, 2010; Rossi et al, 2005), suggesting that blockade of IL-6 in this setting
could be of interest. Indeed, results from clinical trials combining BE-8, a murine mAb
against IL-6, with dexamethasone and high dose melphalan followed by ASCT in myeloma
patients, do indicate that inhibition of IL-6 is clinically beneficial in combination with HDM
regimens. The first study, involving 16 patients with relapsed myeloma, had a complete
remission rate of 37·5%, and an overall response rate of 81·3%, with no significant added
toxicity of BE-8, and overall survival was 68·1% at 16 months (Moreau et al, 2000). In the
second study, BE-8 was administered 1 day prior to dexamethasone, and was given daily
until haematological recovery following ASCT. In 24 newly diagnosed myeloma patients,
there was a complete remission rate of 16·7%, a very good partial response rate of 37·5%
and a partial response rate of 25%, with reduced toxicity compared to HDM alone (Rossi et
al, 2005). Overall survival was 68·2% at 5 years, and median event-free survival was 35
months (Rossi et al, 2005). Several patients had extremely high IL-6 levels beginning 6–8 d
following ASCT, and BE-8 was unable to reach a high enough concentration to effectively
inhibit IL-6 in these patients due to the short, 3–4 d half-life of this antibody (Rossi et al,
2005). The authors suggested that an anti-IL-6 antibody, such as siltuximab, with a longer
half-life of 17–18 d (Puchalski et al, 2010), may be able to achieve a higher circulating
concentration. In a recent phase I/II study in patients with progressive metastatic renal cell
carcinoma, siltuximab administered at 6 mg/kg every 2 weeks achieved a peak serum
concentration above 100 μg/ml directly following administration, and maintained a
concentration above 21 μg/ml throughout the course of the study (Puchalski et al, 2010).
Following this regimen, siltuximab was able to suppress serum C-reactive protein (CRP, a
marker of IL-6 activity) in renal cell carcinoma patients when CRP was ≤30 mg/l prior to
treatment (Puchalski et al, 2010).
These findings together support the evaluation of siltuximab in the clinic in combination
with melphalan-based therapies, including either high dose therapy in transplant-eligible
patients, or standard dose melphalan-containing induction regimens in transplant-ineligible
patients, such as with the combination of bortezomib, melphalan, and prednisone (VMP).
Indeed, a randomized trial is currently underway comparing the activity of VMP to that of
siltuximab with VMP (NCT00911859). Data from this study will be helpful in determining
the clinical benefit of IL-6 blockade as part of therapy for newly diagnosed multiple
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myeloma, and in further validating the hypothesis that siltuximab enhances the clinical
activity of melphalan.
Supplementary Material
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Siltuximab enhances the anti-proliferative effects of melphalan. (A) The effect of IL-6
blockade alone was evaluated in IL-6-dependent HMCLs, which were seeded in 96-well
plates. They were then treated for 72 h with increasing doses of the IL-6 neutralizing
monoclonal antibody siltuximab, and cell viability was assessed using the WST-1 reagent.
Results were expressed as a percentage of the vehicle treated controls, which were
arbitrarily set at 100%. Median inhibitory siltuximab concentrations (IC50 values) were
calculated from the dose-response curve using GraphPad Prism software, and are the mean
of three experiments. Bars represent the standard deviation (SD). (B) KAS-6/1 cells were
pretreated with either siltuximab or the F105 control antibody at 0·05 μg/ml for 24 h,
followed by addition of melphalan (Mel) at the concentrations indicated for 48 h. The
WST-1 assay was used to assess cell viability, which was expressed as a percentage of the
F105 isotype matched, antibody-treated control. All data represent the means of three
experiments, bars indicate SD, and significance was evaluated with the t-test. Significant
values at P < 0·05 are indicated with ‘*’, while P < 0·01 is indicated by ‘**’. (C) INA-6 cells
were pretreated with either siltuximab or F105 at 0·05 μg/ml for 24 h, then treated with
melphalan, and analysed as described in the legend to panel B. (D) ANBL-6 cells were
pretreated with either siltuximab or F105 at 1·0 μg/ml for 24 h, and then treated with
melphalan and analysed as described in the legend to panel B.
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IL-6 blockade with siltuximab increases melphalan-induced apoptosis. (A) KAS-6/1 cells
were pretreated with 0·5 μg/ml siltuximab or F105 for 24 h, followed by treatment with
melphalan at the indicated concentrations for 48 h. Apoptosis was measured by flow
cytometry on cells stained with FITC-conjugated Annexin V and the DNA binding dye TO-
PRO-3. The bar graph (upper panel) presents the mean proportion of Annexin V+ cells from
two replicates, which are representative of three independent experiments. Bars indicate SD,
significance was evaluated with the t-test. *, P < 0·05, **P < 0·01. In the lower panel, a
representative FACS profile from one experiment with 2 μmol/l melphalan is shown, and
the percentage of cells that were Annexin V+ (right upper + right lower quadrants) is
indicated in the upper right. (B) INA-6 cells were pretreated with 0·1 μg/ml siltuximab or
F105 for 24 h, then treated with melphalan, and data were acquired, analysed, and presented
as above.
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Siltuximab enhances activation of the extrinsic and intrinsic apoptotic pathways in
combination with melphalan. (A) KAS-6/1 cells were pretreated with siltuximab or F105 at
2·5 μg/ml for 24 h, after which melphalan was added for 48 h. To measure caspase
activation, the cells were incubated for 30 min with irreversible caspase-3 (FITC-DEVD-
FMK, upper panel), caspase-8 (FITC-IETD-FMK, middle panel), or caspase-9 (FITC-
LEHD-FMK, lower panel) inhibitors, which bound the activated caspases, and then analysed
by flow cytometry. Drug-specific caspase activation was calculated using the formula: [(%
FITC positive cells in treated sample−% FITC positive cells in vehicle control sample)/
(100−% FITC positive cells in vehicle control sample)] × 100. Bar graphs indicate the mean
drug-specific caspase activation from three independent experiments, together with the SD.
*, P < 0·05, **P < 0·01 by the t-test. (B) INA-6 cells were pretreated with siltuximab or
F105 at 0·1 μg/ml for 24 h, then treated with melphalan, and data were acquired, analysed,
and presented as above.
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Siltuximab enhances melphalan cytotoxicity in the presence of stroma. (A) KAS-6/1 cells
were plated either alone or on top of adhered HS5-GFP stromal cells and allowed to attach
overnight (upper panel). Cultures were then treated with the indicated concentrations of
siltuximab for 72 h, harvested by trypsinizing to collect all cells, and stained with PE-
conjugated Annexin V and the DNA dye TO-PRO-3. A total of 10 000 events were analysed
by flow cytometry to detect the proportion of cells undergoing programmed cell death.
Stromal cells were separated from the myeloma cells by their intense green fluorescence.
Drug-specific apoptosis was calculated using the equation: [(% Annexin V positive cells in
treated sample−% Annexin V positive cells in vehicle control)/(100−% Annexin V positive
cells in vehicle control)] × 100. Bar graphs indicate the mean drug-specific apoptosis from
three independent experiments, along with the SD, with ‘ns’ indicating a trend that was not
statistically significant, ‘*’ indicating a P < 0·05, and ‘**’ indicating a P < 0·01 by the t-test.
In the lower panel, KAS-6/1 cells were pretreated with siltuximab or F105 for 24 h at 10 μg/
ml in the presence of stromal cells, followed by the indicated concentrations of melphalan
for another 48 h. They were then processed, analysed, and data are presented as indicated
above. Positive control experiments were performed with KAS-6/1 or INA-6 cells treated
with vehicle or dexamethasone either in the absence or presence of HS5-GFP cells, and
demonstrated the ability of these stromal cells to protect myeloma cells from apoptosis (data
not shown). (B) INA-6 cells were plated either alone or on top of adhered HS5-GFP stromal
cells and allowed to attach overnight (upper panel). Cultures were then treated with the
indicated concentrations of siltuximab for 72 h, then harvested, stained with FITC-
conjugated Annexin V and TO-PRO-3, and analysed as described above. The data are
presented as indicated in panel A. In the lower panel, INA-6 cells were pretreated with
siltuximab or F105 at 0·1 μg/ml in the presence of stromal cells for 24 h, followed by the
indicated concentrations of melphalan for another 48 h. They were then processed and
analysed, and the data are presented as indicated in panel A above.
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Bak and Bax are activated by siltuximab and melphalan. (A) KAS-6/1 cells were treated
with the indicated concentrations of siltuximab or F105 control antibody for 72 h. They were
then permeabilized and exposed to primary antibodies raised against the active forms of Bak
(left panel) or Bax (right panel), followed by an Alexa Fluor® 488 conjugated secondary
antibody. Fluorescence was detected by flow cytometry. The percentage of cells with
activated Bak or Bax is graphed as the mean of three independent experiments. Error bars
indicate the SD, with ‘*’ indicating a P < 0·05, and ‘**’ indicating a P < 0·01 by the t-test.
(B) KAS-6/1 cells were pretreated for 24 h with 1 μg/ml of either siltuximab or F105,
followed by melphalan at the indicated concentrations for 48 h. Bak (left panel) or Bax
(right panel) activation was then assayed, analysed, and presented as described above. Error
bars indicate the SD, with ‘ns’ indicating a trend that did not reach statistical significance,
‘*’ indicating a P < 0·05, and ‘**’ indicating a P < 0·01 by the t-test. (C) KAS-6/1 cells were
pretreated with 2·5 μg/ml of either siltuximab (+lanes) or F105 (−lanes) for 24 h, followed
by either vehicle or 2 μmol/l melphalan for 48 h. Cells were then lysed in buffer containing
1% CHAPS, and extracts were subjected to immunoprecipitation with an antibody that
recognizes only the activated form of Bak. Immunoprecipitated Bak and the IgG heavy
chain were then detected by Western blotting. A representative Western blot is shown from
one of two independent experiments. (D) INA-6 cells were pretreated with 0·1 μg/ml of
either siltuximab (+lanes) or F105 (−lanes) for 24 h, followed by either vehicle or 2 μmol/l
melphalan for 48 h. Cells were then subjected to immunoprecipitation to detect their content
of activated Bak as described above.
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Siltuximab activates Bid and reduces the activation status of the Akt pathway. (A) INA-6
cells were pretreated with 0·1 μg/ml siltuximab (+lanes) or F105 (−lanes) for 24 h followed
by 48 h with 2 μmol/l melphalan or vehicle control. Bid and tBid were detected in cellular
lysates by Western blotting. A representative Western blot is shown from one of two
independent experiments. (B) INA-6 cells were treated with 0·5 μg/ml siltuximab (+lanes)
or F105 (−lanes) for the indicated times. Cellular lysates were probed by Western blotting
for Bid and tBid. A representative Western blot is shown from one of two independent
experiments. (C) KAS-6/1 cells were simultaneously exposed to 0·5 μg/ml of either
siltuximab (+lanes) or F105 (−lanes), and either vehicle control or melphalan at the
indicated concentration. Cellular lysates prepared from cells treated as above for 8 h were
probed by Western blotting to detect the levels of Akt, phospho-Akt, p70 S6 kinase, and
phospho-p70, as well as β-actin as a loading control. Lysates prepared from cells treated as
above for 24 h were probed by Western blotting to detect the levels of phospho-4E-BP1. A
representative Western blot is shown from one of two independent experiments. (D) INA-6
cells were treated and analysed as described above in the legend to panel C.
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Siltuximab and melphalan are active against primary plasma cells. (A) Primary CD138+
plasma cells isolated from the bone marrow aspirates of three patients with multiple
myeloma were pretreated with either 10 μg/ml siltuximab or F105 control antibody for 24 h.
They were then exposed to the indicated concentrations of melphalan or vehicle for another
48 h. Cell viability was then measured using the WST-1 reagent, and is presented as the
percent viability compared to the vehicle-treated controls (F105 plus acid saline/acid
ethanol). All data represent the mean of a single experiment performed in triplicate, with
bars indicating SD. Significance was evaluated with the t-test, with ‘ns’ indicating a trend
that did not reach statistical significance. Significant values at P < 0·05 are indicated with
‘*’, while P < 0·01 is indicated by ‘**’. (B) Primary CD138+ plasma cells isolated from the
bone marrow aspirate of one patient with amyloidosis were evaluated as described in panel
A. Error bars indicate the SD, ‘*’ indicating a P < 0·05, and ‘**’ indicating a P < 0·01 by the
t-test. (C) Primary CD138+ plasma cells isolated from the bone marrow aspirate of one
patient with monoclonal gammopathy of undetermined significance (MGUS) were evaluated
as described in panel A. (D) The HS5-GFP stromal cell line was pretreated with either 10
μg/ml siltuximab or F105 control antibody for 24 h, and then treated with melphalan and
analysed as described in panel A.
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